

Minutes of the

1st Annual General Meeting

of the shareholders of

medmix AG

in Winterthur

held on

Tuesday, 12. April 2022, 10.00 am

at

Neuwiesenstrasse 15

Winterthur

The Chairman of the Board of Directors, Greg Poux-Guillaume, formally opens the 1st Annual General Meeting of medmix Ltd and notes the following:

The invitation of shareholders to today's Annual General Meeting was published in the Swiss Official Gazette of Commerce on 16 March 2022. This means that the statutory notice period of 20 days has been complied with. The agenda and the proposals were also sent to the shareholders on 16 March 2022.

Pursuant to Art. 696 of the Swiss Code of Obligations (“CO”), the annual report, the compensation report and the auditors' reports must be made available for inspection by shareholders at the company's registered office no later than 20 days before the Annual General Meeting. This is the case. The complete annual report, including the compensation report and the auditors' reports, have been available for review and download on the website since February 22, 2022.

In advance of the Annual General Meeting, no requests for the inclusion of items on the agenda were received from shareholders, nor were there any proposals or questions regarding items on the agenda.

The meeting is therefore convened in accordance with the law and the Articles of Association and constitutes a quorum with regard to the published agenda items.

Based on the COVID-19 Ordinance 3, as extended by the Swiss Federal Council, shareholders are not allowed to attend the Annual General Meeting in person this year. Instead, shareholders were able to authorize the independent proxy to vote according to their instructions by means of a written or electronic proxy.

Due to these circumstances, the members of the Board of Directors and the Executive Committee, apart from the Chairman and the Vice-Chairman of the Board of Directors, are not present in person at today's Annual General Meeting.

31'784'987 shares with a total par value of CHF 317'849.87 are represented by the independent proxy, corresponding to 77.03% of the share capital.

The auditors, KPMG AG, Zurich, are represented by Mr. Simon Niklaus.

Greg Poux-Guillaume also welcomes the independent proxy, Proxy Voting Services GmbH, represented by Mr. Christoph Helbling, attorney-at-law in Zurich.

In accordance with Art. 14 of the Articles of Association, today's Annual General Meeting is chaired by the Chairman of the Board of Directors. Greg Poux-Guillaume appoints Philippe Fuchs as secretary and vote counter. The Chairman also welcomes Martin Schmuki, the notary public, who prepares the public deed of today's resolutions.

The Annual General Meeting shall pass resolutions on agenda items 1 to 8 by an absolute majority of the votes represented pursuant to Art. 15 para. 1 of the Articles of Association and on agenda item 9 concerning the proposed relocation of the registered office by a 2/3 majority of the votes represented pursuant to Art. 16 para. 1 of the Articles of Association in conjunction with Art. 704 para. 1 CO.

The Annual General Meeting will be webcast live today via the Internet (medmix website).

Speech by Greg Poux-Guillaume, Chairman of the Board of Directors of medmix Ltd:

On behalf of the medmix Board of Directors and management team, the Chairman thanks the shareholders for joining medmix at its first Annual General Meeting.

This past year has of course been a crucial year for medmix. Following shareholder approval in September last year, medmix became independent and it made its debut on the Swiss Stock Exchange. The spin-off was a unique opportunity for medmix to accelerate its growth and unlock significant value for shareholders, and with the concurrent capital increase medmix was able to raise gross proceeds of CHF 315 million, with an order book many times oversubscribed. In the meantime, the shareholder base progressively stabilized, with some historical Sulzer investors focused on yield stocks or industrials rotating out, and new investors focused on growth stocks or healthcare building their positions in medmix.

2021 has also been a year of turbulence as recovering economies around the world had to learn to adapt not only to recurring waves of the pandemic and lockdowns, but also to supply chain disruptions, shortages of raw materials and energy price hikes.

Thanks to medmix' swift action, its business had recovered to pre-pandemic levels by the second half of 2021, and the teams worked tirelessly to keep all people safe and overcome these challenges, ensuring seamless supply for medmix' customers and tapping into pent-up demand as customers restocked.

Now, fragile recoveries are facing a new challenge in the form of the devastating war in Ukraine. The humanitarian crisis as well as the economic effects are being felt around the world and will likely exacerbate existing difficulties with regards to raw materials, supply chain disruptions and the rising cost of energy as well as shortages.

Throughout these difficulties, medmix' business has proved itself strong and resilient. In 2021 medmix returned excellent results, meeting or surpassing the targets that were communicated to the markets. medmix closed the financial year with a revenue of CHF 457.3 million, an increase of 30.2% compared to 2020. This also marks a significant 8.7% increase compared to the pre-pandemic CHF 420.7 million in 2019. Its organic growth rate was 21.5% compared to the previous year. In its strategic growth market, Healthcare, medmix was able to drive a 63.7% increase against the previous year. Furthermore, medmix achieved its first-year target of 25% EBITDA profit margins, which medmix hopes to further increase this year.

With regards to its governance, medmix is pleased to present today five new members of the Board of Directors, pending your approval. Rob ten Hoedt, Daniel Flammer, Barbara Angehrn, René Willi and David Metzger all have a rich background of international leadership and bring a diverse range of relevant experience in medmix' strategic focus markets. They will make excellent additions to the Board of Directors, and together with medmix' strong Executive Management team, position medmix well to continue its growth

path. As communicated in February, Jill Lee has decided not to stand for re-election, and on behalf of the Board of Directors, the Chairman thanks her warmly for the exceptional contribution she made to facilitating medmix' spin-off and to medmix' beginnings as an independent company.

Looking ahead, the Chairman remains optimistic despite the new geopolitical challenges which have led to increased volatility. medmix' global footprint, its strong position in niche markets as well as its agility are essential assets that will help medmix weather the storm and demonstrate yet again its resilience.

In 2022, medmix is aiming for 8 to 10% growth in revenue. Growing revenue in the more profitable Healthcare business area faster than in Consumer & Industrial will drive its adjusted EBITDA margin to 26%. In the medium term, medmix' aim is to achieve a compound annual growth rate (CAGR) of 8% in revenue and an increase in adjusted EBITDA margin to 30% through continued faster growth in the Healthcare business area and operational leverage. To reach these goals, medmix plans to increase its production capacities in 2022. medmix also intends to make strategic acquisitions that will enable it to broaden its product portfolio in Healthcare and expand geographically, with a focus on China.

Finally, the Chairman thanks the shareholders for their trust and confidence in medmix and for accompanying it as medmix spreads its wings as an independent company. This is just the beginning of an exciting journey for medmix, and the Chairman is happy to have the shareholders with him.

At today's Annual General Meeting, a total of 31'784'987 votes are represented by the independent proxy, corresponding to 77.03% of the share capital. The absolute majority of votes is therefore 15'892'494. The qualified majority of 2/3 of the votes represented regarding agenda item 9 is 21'189'992.

Agenda item 1

"ANNUAL REPORT 2021"

Greg Poux-Guillaume explains that this agenda item is divided into two sub-items, agenda item 1.1, "**Business review, financial statements of medmix Ltd and consolidated financial statements 2021, reports of the Auditors**", and agenda item 1.2, "**Advisory vote on the compensation report 2021**".

Agenda item 1.1

"BUSINESS REVIEW, FINANCIAL STATEMENTS OF MEDMIX LTD AND CONSOLIDATED FINANCIAL STATEMENTS 2021, REPORTS OF THE AUDITORS"

The annual report, containing the business review, the financial statements of medmix Ltd and the consolidated financial statements, as well as the reports of the statutory auditors, are available.

Greg Poux-Guillaume reiterates the key numbers from the income statement of the holding company, medmix Ltd, for the period starting September 20, 2021, and ending December 31, 2021. The parent company's accounts closed with income of CHF 549k and expenses of CHF 1.047 million, resulting in a loss of CHF 498k.

Greg Poux-Guillaume mentions that medmix Ltd's statutory financial statements have been prepared according to the accounting principles of the Swiss Code of Obligations.

The auditors' reports are included in the "financial section" of the annual report on pages 157 et seqq. (for the consolidated financial statements) and on pages 174 et seqq. (for the financial statements of medmix Ltd). The page numbers refer to the annual reports that can be downloaded in PDF format from the website. Greg Poux-Guillaume thanks KPMG AG for their work.

Prior to the Annual General Meeting, the representative of KPMG AG, who is present, indicated that he had no verbal additions to make to the reports.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the business review, the financial statements of medmix Ltd and the consolidated financial statements 2021 or the auditors' reports prior to the Annual General Meeting.

The Board of Directors proposes that the business review, the financial statements of medmix Ltd and the consolidated financial statements 2021 be approved.

Greg Poux-Guillaume announces the votes represented by the independent proxy:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	31'727'935
No	17'408
Abstentions	39'644

Greg Poux-Guillaume notes that the shareholders have approved the business review, the financial statements of medmix Ltd and the consolidated financial statements 2021.

In the past year, which was operationally challenging, medmix achieved many things. This would not have been possible without the extraordinary performance of medmix' employees. On behalf of the Board of Directors and the Executive Committee, Greg Poux-Guillaume thanks all the employees for their great commitment and performance.

Agenda item 1.2

"ADVISORY VOTE ON COMPENSATION REPORT 2021"

Greg Poux-Guillaume explains that agenda item 1.2 is a non-binding advisory vote.

The compensation report sets out the basic principles of medmix' compensation policy and plans, as well as the compensation of the members of the Board of Directors and the

Executive Committee. Greg Poux-Guillaume further explains the compensation policy of medmix for the Board of Directors and the Executive Committee.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the compensation report 2021 prior to the Annual General Meeting.

The Board of Directors proposes that the compensation report 2021 as set out on pages 62 et seqq. of the annual report be approved.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	28'857'525
No	2'864'763
Abstentions	62'699

Greg Poux-Guillaume notes that the shareholders have approved the compensation report 2021 with a clear majority and thanks them for this.

Agenda item 2

"APPROPRIATION OF ANNUAL RESULT"

Greg Poux-Guillaume explains that medmix pursues a dividend policy that takes into account the company's liquidity as well as its economic situation.

The proposal of the Board of Directors includes a gross dividend, before deduction of 35% Swiss withholding tax, of CHF 0.50 per share, payable on April 20, 2022. All shares held by medmix Ltd and its subsidiaries as treasury shares on the record date are not entitled to dividends.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the appropriation of the annual result prior to the Annual General Meeting.

The Board of Directors proposes to distribute the total balance of CHF 24'502'382, consisting of the net loss for 2021 of CHF 497'618 and the allocation from free reserves of CHF 25 million as follows: CHF 20'556'185 as ordinary dividend and CHF 3'946'197 as carry forward.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	31'745'466
No	17'570
Abstentions	21'951

Greg Poux-Guillaume notes that the Annual General Meeting has approved the appropriation of the annual result proposed by the Board of Directors.

Agenda item 3 "DISCHARGE"

Greg Poux-Guillaume reminds the shareholders that according to Art. 695 CO, those persons who have participated in the management of the company do not have the right to vote on the present agenda item.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding this agenda item prior to the Annual General Meeting. He further reminds the shareholders that the global discharge of all the members of the Board of Directors and the Executive Committee will be voted on.

The Board of Directors proposes that discharge be granted to the members of the Board of Directors and the Executive Committee for the financial year 2021.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'741'987
Absolute majority	15'870'994
Yes	30'882'825
No	812'382
Abstentions	46'780

Greg Poux-Guillaume notes that the Annual General Meeting has granted discharge to the Board of Directors and the Executive Committee. He thanks the shareholders for the trust they have placed in the Board of Directors and the Executive Committee.

Agenda item 4 "COMPENSATION OF THE MEMBERS OF THE BOARD OF DIRECTORS AND THE EXECUTIVE COMMITTEE"

Greg Poux-Guillaume comes to the vote on the compensation of the Board of Directors and the Executive Committee. He mentions that agenda item 4 is divided into two sub-

items with two separate votes: part 1, "**Compensation of the Board of Directors**", and part 2, "**Compensation of the Executive Committee**".

For detailed explanations on the approval of the submitted compensation, Greg Poux-Guillaume refers to the separate report of the Board of Directors, which shareholders received with the invitation to this Annual General Meeting.

The Chairman comments on the remuneration of the Board of Directors as follows: The maximum total amount submitted for approval relates to the remuneration of the Board of Directors for the term from today's Annual General Meeting to the Annual General Meeting 2023.

Greg Poux-Guillaume mentions that the Board of Directors has proposed additional members for election at this year's Annual General Meeting, increasing the total number of Board members to seven. The proposed maximum total amount of CHF 1'500'000 is based on the compensation for these seven members of the Board of Directors. The members of the medmix Board of Directors receive only a fixed compensation in order to ensure their independence. They do not receive any variable or performance-related compensation and are not entitled to participate in medmix' pension plans. The compensation of the Board of Directors is partly paid in cash and partly in restricted stock units.

Greg Poux-Guillaume subsequently explains the compensation of the Executive Committee. The maximum total amount proposed relates to the compensation of the Executive Committee for the financial year 2023. He mentions that the Board of Directors has announced its intention to enlarge the Executive Committee to better reflect the growth ambitions of medmix. The proposed amount of CHF 8'500'000 covers the total compensation of the members of the enlarged Executive Committee. The total compensation consists of a fixed base salary and a variable component. The variable component comprises a short-term performance-related bonus (in cash) and a long-term performance-related performance share unit (PSU) plan. This system is designed to motivate above-average performance and to recognize this performance accordingly.

The Chairman mentions that this is a maximum amount. In accordance with legal requirements, the calculation of the maximum total amount of compensation for the Executive Board takes into account the potential maximum amounts under the variable component of compensation, i.e. both the short-term and long-term incentive systems.

The compensation actually paid out will be disclosed in the compensation report for the financial year 2023, which is submitted to the shareholders for a consultative vote.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding this agenda item prior to the General Meeting.

Agenda item 4.1

"COMPENSATION OF THE BOARD OF DIRECTORS"

The Annual General Meeting votes on the approval of the total amount for the remuneration of the Board of Directors for the term from the Annual General Meeting 2022 until the end of the Annual General Meeting 2023 in the maximum amount of CHF 1'500'000.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions.

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'693'652
No	1'026'883
Abstentions	64'452

Greg Poux-Guillaume notes that the Annual General Meeting approved the maximum total compensation of the Board of Directors for the term from the Annual General Meeting 2022 until the end of the Annual General Meeting 2023.

Agenda item 4.2
"COMPENSATION OF THE EXECUTIVE COMMITTEE"

Greg Poux-Guillaume continues with the vote on agenda item 4.2:

The Annual General Meeting votes on the approval of the total amount for the compensation of the Executive Committee for the financial year 2023 in the maximum amount of CHF 8'500'000.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'989'875
No	739'886
Abstentions	55'226

Greg Poux-Guillaume notes that the Annual General Meeting has approved the maximum total compensation of the Executive Committee for the financial year 2023.

Agenda item 5
"ELECTION OF THE BOARD OF DIRECTORS"

Greg Poux-Guillaume mentions that agenda item 5 is divided into three sub-items with separate votes, namely agenda item 5.1 "**Re-election of the Chairman of the Board of Directors**", agenda item 5.2 "**Re-election**", and agenda item 5.3 "**Elections of new members**".

Agenda item 5.1:**"RE-ELECTION OF THE CHAIRMAN OF THE BOARD OF DIRECTORS"**

As the Chairman is personally involved in this agenda item, he hands this agenda item over to the Vice-Chairman, Marco Musetti.

Marco Musetti explains that Greg Poux-Guillaume was elected as a member and Chairman of the Board of Directors at the incorporation of medmix in September 2021. He further mentions that Greg Poux-Guillaume is also a member of the Remuneration Committee as well as the Audit Committee.

Marco Musetti notes that no questions or counterproposals have been received regarding the re-election of the Chairman of the Board of Directors prior to the Annual General Meeting.

The Board of Directors proposes to re-elect Greg Poux-Guillaume as member of the Board of Directors and Chairman of the Board of Directors for a term until the end of the next Annual General Meeting.

Marco Musetti announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	27'402'604
No	4'357'019
Abstentions	25'364

Marco Musetti notes that the Annual General Meeting has re-elected Greg Poux-Guillaume to the Board of Directors and as Chairman of the Board of Directors for a term until the end of the next Annual General Meeting. Marco Musetti congratulates Greg Poux-Guillaume on his re-election and hands the chair back to him.

Agenda item 5.2:**"RE-ELECTIONS"**

Greg Poux-Guillaume explains that up to today's Annual General Meeting, the Board of Directors of medmix Ltd consisted of three individuals with an international background, including him as Chairman. Jill Lee has decided not to stand for re-election as member of the Board of Directors of medmix. On behalf of medmix, Greg Poux-Guillaume thanks Jill Lee for her outstanding service as a member of the Board of Directors since the incorporation of the company in September last year. She has brought a wealth of knowledge and experience in finance, technology and leadership to medmix and the Board of Directors wishes her all the best for her future endeavors.

The Board of Directors proposes to re-elect Marco Musetti for a term until the end of the next Annual General Meeting. Marco Musetti has also been a member of the Board of Directors since the incorporation of medmix Ltd in September 2021. He is Vice-Chairman of the Board of Directors and the Chairman of the Remuneration Committee.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the re-election of Marco Musetti prior to the Annual General Meeting and proceeds with his re-election.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	29'448'240
No	2'310'728
Abstentions	26'019

Greg Poux-Guillaume notes that the Annual General Meeting has re-elected Marco Musetti to the Board of Directors for a term until the end of the next Annual General Meeting.

**Agenda item 5.3:
"NEW ELECTIONS"**

So far, the Board of Directors consisted of three members, including Greg Poux-Guillaume as Chairman. However, the Articles of Association of medmix Ltd allow up to seven members. To support the future development of medmix and due to the retirement of Jill Lee, the Board of Directors shall be supplemented by five members.

Greg Poux-Guillaume presents the new members of the Board of Directors standing for election:

Rob ten Hoedt is Executive Vice President and President EMEA at Medtronic.

Daniel Flammer is a Managing Partner of AR Financial Advisory AG in Zurich and the Chairman of Tiwel Holding AG, medmix' principal shareholder. Daniel will represent Tiwel Holding AG on medmix' Board of Directors.

Barbara Angehrn is Chief Business Officer and member of the Executive Committee of Vifor Pharma.

René Willi is CEO of Global Oral Reconstruction Group at Henry Schein and a member of Henry Schein's Executive Management Committee.

David Metzger is Managing Director Investments of Liwet Holding AG. David will also represent medmix' principal shareholder, Tiwel Holding AG, in the Board of Directors.

Greg Poux-Guillaume notes that no questions or counterproposals have been received prior to the General Meeting.

Greg Poux-Guillaume now comes to the new elections under agenda item 5.3 and starts with the election of Rob ten Hoedt under agenda item 5.3.1.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	27'081'569
No	4'668'892
Abstentions	34'526

Greg Poux-Guillaume notes that the Annual General Meeting has elected Rob ten Hoedt to the Board of Directors for a term until the end of the next Annual General Meeting.

He continues with the election of Daniel Flammer under agenda item 5.3.2.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'783'283
No	969'898
Abstentions	31'806

Greg Poux-Guillaume notes that the Annual General Meeting has elected Daniel Flammer to the Board of Directors for a term until the end of the next Annual General Meeting.

New election of Barbara Angehrn under agenda item 5.3.3.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	31'707'828
No	45'672
Abstentions	31'487

Greg Poux-Guillaume notes that the Annual General Meeting has elected Barbara Angehrn to the Board of Directors for a term until the end of the next Annual General Meeting.

New election of René Willi under agenda item 5.3.4.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'943'611
No	810'152
Abstentions	31'224

Greg Poux-Guillaume notes that the Annual General Meeting has elected René Willi to the Board of Directors for a term until the end of the next Annual General Meeting.

New election of David Metzger under agenda item 5.3.5.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'848'456
No	906'615
Abstentions	29'916

Greg Poux-Guillaume notes that the Annual General Meeting has elected David Metzger to the Board of Directors for a term until the end of the next Annual General Meeting.

Greg Poux-Guillaume mentions that the Board of Directors will be reconstituted following the Annual General Meeting and that the relevant decisions will be published today. This concerns the election of the vice-chairperson of the Board of Directors, the election of the chairperson of the Remuneration Committee, as well as the election and constitution of the Audit Committee, i.e. the election of the members and the chairperson.

Agenda item 6 "ELECTION OF THE REMUNERATION COMMITTEE"

Agenda item 6.1: "RE-ELECTION"

As the Chairman is personally involved in this agenda item, he hands this agenda item over to the Vice-Chairman, Marco Musetti.

Marco Musetti mentions that the Board of Directors proposes that the shareholders re-elect Greg Poux-Guillaume as member of the Remuneration Committee for a term until the end of the next Annual General Meeting. Greg Poux-Guillaume was elected to the Board of Directors as Chairman for the first time at the incorporation of medmix in September 2021 and has been re-elected as Chairman today. He has been a member of the Remuneration Committee and a member of the Audit Committee since 2021.

He notes that no questions or counterproposals have been received regarding the re-election of Greg Poux-Guillaume as member of the Remuneration Committee prior to the Annual General Meeting.

Marco Musetti announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	25'460'212
No	6'286'918
Abstentions	37'857

Marco Musetti notes that the Annual General Meeting has re-elected Greg Poux-Guillaume as a member of the Remuneration Committee for a term until the end of the next Annual General Meeting. He congratulates Greg Poux-Guillaume on his re-election.

Marco Musetti further mentions that he and Jill Lee will not stand for re-election and hands the chair back to Greg Poux-Guillaume.

**Agenda item 6.2:
"ELECTION OF NEW MEMBERS "**

Greg Poux-Guillaume continues with the election of two new members of the Remuneration Committee. He starts with the election of Rob ten Hoedt under agenda item 6.2.1.

The Board of Directors proposes that the shareholders elect Rob ten Hoedt as member of the Remuneration Committee for a term until the end of the next Annual General Meeting.

Greg Poux-Guillaume notes that no questions or counterproposals have been received prior to the Annual General Meeting.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	27'057'107
No	4'684'940
Abstentions	42'940

Greg Poux-Guillaume notes that the Annual General Meeting has elected Rob ten Hoedt as a member of the Remuneration Committee for a term until the end of the next Annual General Meeting. He congratulates Rob ten Hoedt on his election.

He continues with the election of Barbara Angehrn as member of the Remuneration Committee under agenda item 6.2.2.

The Board of Directors proposes that the shareholders elect Barbara Angehrn as member of the Remuneration Committee for a term until the end of the next Annual General Meeting.

Greg Poux-Guillaume notes that no questions or counterproposals have been received prior to the Annual General Meeting.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	31'138'546
No	605'531
Abstentions	40'910

Greg Poux-Guillaume notes that the Annual General Meeting has elected Barbara Angehrn as a member of the Remuneration Committee for a term until the end of the next Annual General Meeting. He congratulates Barbara Angehrn on her election.

Agenda item 7 "RE-ELECTION OF AUDITORS"

Greg Poux-Guillaume continues with the re-election of the auditors.

The Board of Directors proposes that KPMG AG, Zurich, be re-elected as auditors. Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the re-election of the auditors prior to the Annual General Meeting.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	30'907'654
No	849'898
Abstentions	27'435

Greg Poux-Guillaume notes that the Annual General Meeting has re-elected KPMG AG as auditors and congratulates KPMG AG on its re-election.

Agenda item 8
"RE-ELECTION OF INDEPENDENT PROXY"

Greg Poux-Guillaume continues with the next agenda item, the re-election of the independent proxy.

The Board of Directors proposes to re-elect Proxy Voting Services GmbH, Zurich, as independent proxy for a term until the end of the next Annual General Meeting. Proxy Voting Services GmbH meets the requirements for independence. It is not connected to medmix through any other activities.

Greg Poux-Guillaume notes that no questions or counterproposals have been received regarding the re-election of the independent proxy prior to the Annual General Meeting.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Absolute majority	15'892'494
Yes	31'755'610
No	7'958
Abstentions	21'419

Greg Poux-Guillaume notes that the Annual General Meeting has re-elected Proxy Voting Services GmbH as independent proxy for a term until the end of the next Annual General Meeting and congratulates Proxy Voting Services GmbH on its re-election.

Agenda item 9
" TRANSFER OF REGISTERED OFFICE"

Greg Poux-Guillaume comes to the last agenda item, the relocation of medmix Ltd's registered office under agenda item 9.

He mentions that medmix Ltd has moved into new offices in April in Baar, Zug. The Board of Directors therefore proposes to change article 1 of the Articles of Association for the purpose of reflecting the transfer of the registered office. In order for the proposal of the Board of Directors to be accepted, at least two thirds of the votes represented at today's Annual General Meeting must approve the proposed amendment to the Articles of Association in accordance with Art. 16 para. 1 of the Articles of Association in conjunction with Art. 704 para. 1 CO.

Greg Poux-Guillaume notes that no questions or counterproposals have been submitted prior to the Annual General Meeting.

Greg Poux-Guillaume announces the votes represented by the independent proxy and the voting instructions:

Votes represented	31'784'987
Qualified majority	21'189'992
Yes	31'700'479
No	33'595
Abstentions	50'913

Greg Poux-Guillaume notes that the Annual General Meeting has approved the proposed change of the Articles of Association with the necessary two third majority. He mentions that the Articles of Association have been revised accordingly to reflect the change in article 1 and will be registered with the Register of Commerce.

Greg Poux-Guillaume closes this year's Annual General Meeting. He thanks the shareholders for their interest and wishes everyone good health. He expresses the hope that he will again be able to welcome the shareholders in person at the second Annual General Meeting in 2023.

Closing of the meeting: 10.40 am.

The Chairman:



Gregoire Poux-Guillaume

The Secretary and Vote Counter:



Philippe Fuchs